April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Intraocular Pressure Control Using Bimatoprost 0.03% Every Other Night Compared To Every Night
Author Affiliations & Notes
  • Mouhab Aljajeh
    Ophthalmology, Mass Eye & Ear Infirmary, Reading, Massachusetts
  • Tarek A. Shazly
    Ophthalmology, MEEI / HMS, Reading, Massachusetts
  • Mark A. Latina
    Reading Health Center, Reading, Massachusetts
  • Footnotes
    Commercial Relationships  Mouhab Aljajeh, None; Tarek A. Shazly, None; Mark A. Latina, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 234. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mouhab Aljajeh, Tarek A. Shazly, Mark A. Latina; Intraocular Pressure Control Using Bimatoprost 0.03% Every Other Night Compared To Every Night. Invest. Ophthalmol. Vis. Sci. 2011;52(14):234.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare intraocular pressure (IOP) reduction profiles of Bimatoprost 0.03% administered every other night (QOD-HS) compared to every night (QHS) in patients with primary open angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXFG).

Methods: : A retrospective, chart review of 68 eyes of 45 consecutive patients, who were switched from QHS to QOD-HS Bimatoprost, due to intolerable conjunctival hyperemia, between May 2005 and May 2008. IOP in the morning (AM) and afternoon (PM) of the next day after administration (day 1) and the day after (day 2) on QOD-HS regimen was compared to IOP in the AM and PM when they were on QHS regimen, 4-6 weeks after switching to QOD-HS. Mean IOPs and mean diurnal IOP fluctuation on each regimen were compared using Student t-test.

Results: : Mean IOPs on QHS Bimatoprost were 15.9 +/- 3.4 mm Hg in the AM and 15.5 +/- 2.7 mm Hg in the PM, while mean IOPs on QOD-HS were 14 +/- 2 mm Hg (AM) and 14.2 +/- 2.5 mmHg (PM) on day 1, and 14.7 +/- 2.6 mm Hg (AM) and 14.4 +/- 2.4 mmHg (PM) on day 2 after administration. Difference between IOP fluctuation on QHS and QOD-HS day 1 and day 2 respectively were not significant (p= 0.87 and 0.94).

Conclusions: : Every other night dosing of Bimatoprost was effective in controlling IOP in this select group of patients with POAG and PXFG who had troublesome side effects on Bimatoprost 0.03% QHS regimen, and may be considered as an alternative to every day treatment.

Keywords: anterior chamber • aqueous • ciliary processes 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.